Phynova Groupwww.phynova.com TICKER: PYN EXCHANGE:
Phynova Group is a Sino-Western private company focused on the development of botanically based therapeutics for health and personal care. The botanical compounds used in traditional Chinese medicine go through a 'westernised' IP, pre and clinical development process before being commercialised. Two drug candidates are in Phase ll clinical development: Melokinex for post-operative temporary impairment of the gastro-intestinal function especially after abdominal surgery; and PYN17 for the relief of the symptoms of chronic Hep C. Three other compounds are in pre-clinical development: PYN18 (symptoms of dengue fever), PYN22 (obesity and non-fatty liver disease), Phytoback (topical product against MRSA). Consumer and personal care products include: Relivergen (supplement for liver health), InoNorm (blood-glucose control), FatigueFix (relief of fatigue and improvement of sleep) and PhynoRadiance for skin lightening, are at an early development stage.
Drug development program moving forward on track
£1.4m cash at year end, bolstered by subsequent equity placement
Subject to financing, Group's potential not reflected in current share levels
Foreign buyers gorging on UK stocks
Document can be downloaded here: UK plc ‘going for a song’
Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.
Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.
What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.
According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.
Happy investing. Published 27th August 2019